Table 4.
Factors affecting disease-free survival (DFS) and overall survival (OS)
| Factors | No. of patients | DFS | OS | ||||
|---|---|---|---|---|---|---|---|
| 5-Year | 10-Year | p | 5-Year | 10-Year | p | ||
| % | % | % | % | ||||
| Age, years | 0.890 | 0.674 | |||||
| < 50 | 83 | 38.6 | 29.8 | 55.0 | 37.6 | ||
| ≥ 50 | 43 | 37.1 | 29.7 | 48.8 | 34.9 | ||
| Menopausal status | 0.383 | 0.274 | |||||
| Premenopausal | 92 | 36.9 | 28.8 | 50.7 | 33.9 | ||
| Postmenopausal | 34 | 41.2 | 32.4 | 58..8 | 44.1 | ||
| Histological grade | 0.293 | 0.669 | |||||
| 1 or 2 | 92 | 41.3 | 29.8 | 52.8 | 36.0 | ||
| 3 | 13 | 23.1 | 23.1 | 46.2 | 30.8 | ||
| Clinical tumor stage | 0.047 | 0.017 | |||||
| T1–T2 | 23 | 52.2 | 43.5 | 69.6 | 56.5 | ||
| T3–T4 | 103 | 34.9 | 26.6 | 49.1 | 32.2 | ||
| Clinical nodal stage | 0.041 | 0.036 | |||||
| N0/N1/N2 | 107 | 42.0 | 34.2 | 55.1 | 40.0 | ||
| N3 | 19 | 15.8 | 5.3 | 39.1 | 8.4 | ||
| Clinical stage | 0.086 | 0.026 | |||||
| IIIA | 58 | 43.0 | 37.5 | 60.3 | 48.2 | ||
| IIIB | 49 | 40.8 | 30.4 | 49.0 | 32.4 | ||
| IIIC | 19 | 15.8 | 5.3 | 39.1 | 8.4 | ||
| HER2 status | 0.020 | 0.031 | |||||
| Negative | 52 | 47.9 | 37.7 | 67.3 | 45.8 | ||
| Positive | 45 | 28.9 | 22.2 | 46.7 | 31.1 | ||
| HR status | 0.004 | 0.004 | |||||
| Negative | 51 | 23.5 | 19.6 | 37.3 | 25.5 | ||
| Positive | 71 | 49.2 | 37.3 | 65.8 | 45.6 | ||
| Pathological response | 0.030 | 0.003 | |||||
| pCR | 32 | 53.1 | 43.8 | 75.0 | 59.4 | ||
| Non-pCR | 94 | 32.9 | 25.0 | 45.2 | 28.9 | ||
HR hormone receptor, pCR pathological complete response, HER2 human epidermal growth factor receptor 2